Abstract: Non-small cell lung cancer(NSCLC) continues to exhibit a high incidence and mortality worldwide,posing a serious threat to human health.In recent years,the rapid advancement of immunotherapy has profoundly reshaped the therapeutic paradigm for NSCLC,particularly by improving long-term outcomes in the perioperative period.However,with its increasingly widespread clinical use during this period,several critical issues have emerged,including the precise identification of patients most likely to benefit,optimization of therapeutic strategies,evaluation of pathological value,formulation of adjuvant therapy strategies for patients with complete pathological response after surgery,and the management of immune-related adverse events.This review will systematically discuss these key challenges and aims to provide insights that may facilitate the standardized application of perioperative immunotherapy in NSCLC.

Key words: non-small cell lung cancer；perioperative；immunotherapy